| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 21st October 2020 | Steve Gorlin | 5,000 | Open or private purchase | $9.19 | $45,950.00 |
| 15th October 2020 | Steve Gorlin | 100 | Open or private purchase | $10.27 | $1,027.00 |
| 15th October 2020 | Steve Gorlin | 5,000 | Open or private purchase | $10.10 | $50,500.00 |
| 15th October 2020 | Steve Gorlin | 5,000 | Open or private purchase | $10.01 | $50,050.00 |
| 15th October 2020 | Steve Gorlin | 4,000 | Open or private purchase | $10.19 | $40,760.00 |
| 15th October 2020 | Steve Gorlin | 1,000 | Open or private purchase | $10.18 | $10,180.00 |
| 9th October 2020 | Steve Gorlin | 282 | Open or private purchase | $9.61 | $2,710.02 |
| 7th October 2020 | Steve Gorlin | 4,718 | Open or private purchase | $9.42 | $44,443.56 |
| 22nd September 2020 | Steve Gorlin | 15,000 | Open or private purchase | $10.00 | $150,000.00 |
| 19th August 2020 | John C Thomas | 20,000 | Open or private sale | $9.19 | $183,800.00 |
Nant Kwest
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
NantKwest, Inc. engages in the development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
Ticker: NK
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1326110
Employees: 148
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $103 M (0%)
Other Assets, Current: $67 Th (179%)
Assets, Current: $115 M (106%)
Property, Plant and Equipment, Net: $59 M (0%)
Other Assets, Noncurrent: $3 M (0%)
Assets: $196 M (37%)
Accounts Payable, Current: $4 M (127%)
Accrued Liabilities, Current: $7 M (0%)
Liabilities, Current: $17 M (47%)
Liabilities: $27 M (18%)
Common Stock, Value, Issued: $11 Th (10%)
Common Stock, Shares, Issued: $108 M (9%)
Additional Paid in Capital, Common Stock: $870 M (11%)
Retained Earnings (Accumulated Deficit): $701 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $100 Th (-4%)
Stockholders' Equity (Parent): $170 M (0%)
Liabilities and Equity: $196 M (37%)
Research and Development: $14 M (-49%)
Operating Income/Loss: $20 M (-47%)
Other Income, net: $139 Th (-59%)
Provision for income taxes: $4 Th (0%)
News
Wall Street Breakfast: The Week Ahead
22nd November 2020
Stocks To Watch: Eyes On Best Buy, Vaccines And Holiday Cheer
21st November 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020